Abstract: Provided herein are formulations comprising cardiac sarcomere inhibitor (R)-N-(5-(5-ethyl-1,2,4-oxadia-zol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, processes for making such formulations, and methods of treating various cardiac diseases and conditions with such formulations.

Abstract: The present invention relates to a crystal form of (R)-praziquantel and a preparation method and uses thereof. The X-ray diffraction pattern (CuK? radiation) of the crystal form of (R)-praziquantel at 25° C. shows the following diffraction peaks: 2-Theta =6.9±0.2°, 8.3±0.2°, 15.1±0.2°, 17.4±0.2°, 19.8±0.2°, 21.9±0.2°, 24.3 ±0.2° or d=12.74±0.20 ?, 10.61±0.20 ?, 5.87±0.20 ?, 5.09±0.20 ?, 4.48±0.20 ?, 4.06±0.20 ?, 3.66±0.20 ?. Compared to the existing crystal form of praziquantel, the crystal form of the present invention has better solubility, better drug efficacy and better pharmacokinetic characteristics. The preparation method of the present invention has the following advantages: good reproducibility, environmentally friendly, low cost, and able to operate at a normal pressure and temperature, and suitable for large-scale production.

Abstract: The present invention relates to a crystal form of (R)-praziquantel and a preparation method and uses thereof. The X-ray diffraction pattern (CuK? radiation) of the crystal form of (R)-praziquantel at 25° C. shows the following diffraction peaks: 2-Theta=6.9±0.2°, 8.3±0.2°, 15.1±0.2°, 17.4±0.2°, 19.8±0.2°, 21.9±0.2°, 24.3±0.2° or d=12.74±0.20 ?, 10.61±0.20 ?, 5.87±0.20 ?, 5.09±0.20 ?, 4.48±0.20 ?, 4.06±0.20 ?, 3.66±0.20 ?. Compared to the existing crystal form of praziquantel, the crystal form of the present invention has better solubility, better drug efficacy and better pharmacokinetic characteristics. The preparation method of the present invention has the following advantages: good reproducibility, environmentally friendly, low cost, and able to operate at a normal pressure and temperature, and suitable for large-scale production.

Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.

Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.

Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.